These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 32996951)

  • 1. Natural polysaccharide-incorporated hydroxyapatite as size-changeable, nuclear-targeted nanocarrier for efficient cancer therapy.
    Ren X; Yi Z; Sun Z; Ma X; Chen G; Chen Z; Li X
    Biomater Sci; 2020 Sep; 8(19):5390-5401. PubMed ID: 32996951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyaluronic acid ion-pairing nanoparticles for targeted tumor therapy.
    Li W; Yi X; Liu X; Zhang Z; Fu Y; Gong T
    J Control Release; 2016 Mar; 225():170-82. PubMed ID: 26826304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyaluronic acid-capped compact silica-supported mesoporous titania nanoparticles for ligand-directed delivery of doxorubicin.
    Gupta B; Poudel BK; Ruttala HB; Regmi S; Pathak S; Gautam M; Jin SG; Jeong JH; Choi HG; Ku SK; Yong CS; Kim JO
    Acta Biomater; 2018 Oct; 80():364-377. PubMed ID: 30201431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angelica sinensis polysaccharide nanoparticles as a targeted drug delivery system for enhanced therapy of liver cancer.
    Zhang Y; Cui Z; Mei H; Xu J; Zhou T; Cheng F; Wang K
    Carbohydr Polym; 2019 Sep; 219():143-154. PubMed ID: 31151511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyaluronic acid-modified mesoporous silica-coated superparamagnetic Fe
    Fang Z; Li X; Xu Z; Du F; Wang W; Shi R; Gao D
    Int J Nanomedicine; 2019; 14():5785-5797. PubMed ID: 31440047
    [No Abstract]   [Full Text] [Related]  

  • 6. Preparation, characterization and preliminary pharmacokinetic study of pH-sensitive Hydroxyapatite/Zein nano-drug delivery system for doxorubicin hydrochloride.
    Zha L; Wang B; Qian J; Fletcher B; Zhang C; Dong Q; Chen W; Hong L
    J Pharm Pharmacol; 2020 Apr; 72(4):496-506. PubMed ID: 31975457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence.
    Zhang F; Jia Y; Zheng X; Shao D; Zhao Y; Wang Z; Dawulieti J; Liu W; Sun M; Sun W; Pan Y; Cui L; Wang Y; He K; Zhang M; Li J; Dong WF; Chen L
    Acta Biomater; 2019 Dec; 100():352-364. PubMed ID: 31563690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitochondria and nuclei dual-targeted heterogeneous hydroxyapatite nanoparticles for enhancing therapeutic efficacy of doxorubicin.
    Xiong H; Du S; Ni J; Zhou J; Yao J
    Biomaterials; 2016 Jul; 94():70-83. PubMed ID: 27105438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GE11 peptide modified and reduction-responsive hyaluronic acid-based nanoparticles induced higher efficacy of doxorubicin for breast carcinoma therapy.
    Hu D; Mezghrani O; Zhang L; Chen Y; Ke X; Ci T
    Int J Nanomedicine; 2016; 11():5125-5147. PubMed ID: 27785019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mulberry-like dual-drug complicated nanocarriers assembled with apogossypolone amphiphilic starch micelles and doxorubicin hyaluronic acid nanoparticles for tumor combination and targeted therapy.
    Li K; Liu H; Gao W; Chen M; Zeng Y; Liu J; Xu L; Wu D
    Biomaterials; 2015 Jan; 39():131-44. PubMed ID: 25477180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delivery of mitochondriotropic doxorubicin derivatives using self-assembling hyaluronic acid nanocarriers in doxorubicin-resistant breast cancer.
    Liu HN; Guo NN; Guo WW; Huang-Fu MY; Vakili MR; Chen JJ; Xu WH; Wei QC; Han M; Lavasanifar A; Gao JQ
    Acta Pharmacol Sin; 2018 Oct; 39(10):1681-1692. PubMed ID: 29849132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-targeted and multi-stimuli responsive drug delivery system for near-infrared light induced chemo-phototherapy and photoacoustic tomography.
    Feng Q; Zhang Y; Zhang W; Shan X; Yuan Y; Zhang H; Hou L; Zhang Z
    Acta Biomater; 2016 Jul; 38():129-42. PubMed ID: 27090593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioreducible shell-cross-linked hyaluronic acid nanoparticles for tumor-targeted drug delivery.
    Han HS; Thambi T; Choi KY; Son S; Ko H; Lee MC; Jo DG; Chae YS; Kang YM; Lee JY; Park JH
    Biomacromolecules; 2015 Feb; 16(2):447-56. PubMed ID: 25565417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doxorubicin-loaded functionalized selenium nanoparticles for enhanced antitumor efficacy in cervical carcinoma therapy.
    Xia Y; Xiao M; Zhao M; Xu T; Guo M; Wang C; Li Y; Zhu B; Liu H
    Mater Sci Eng C Mater Biol Appl; 2020 Jan; 106():110100. PubMed ID: 31753388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Facile strategy by hyaluronic acid functional carbon dot-doxorubicin nanoparticles for CD44 targeted drug delivery and enhanced breast cancer therapy.
    Li J; Li M; Tian L; Qiu Y; Yu Q; Wang X; Guo R; He Q
    Int J Pharm; 2020 Mar; 578():119122. PubMed ID: 32035259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
    Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
    Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of dual-functional hyaluronic acid-vitamin E succinate micelles on targeting delivery of doxorubicin.
    Wang J; Ma W; Guo Q; Li Y; Hu Z; Zhu Z; Wang X; Zhao Y; Chai X; Tu P
    Int J Nanomedicine; 2016; 11():5851-5870. PubMed ID: 27853369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy.
    Choi KY; Yoon HY; Kim JH; Bae SM; Park RW; Kang YM; Kim IS; Kwon IC; Choi K; Jeong SY; Kim K; Park JH
    ACS Nano; 2011 Nov; 5(11):8591-9. PubMed ID: 21967065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
    He Y; Su Z; Xue L; Xu H; Zhang C
    J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual targeting mesoporous silica nanoparticles for inhibiting tumour cell invasion and metastasis.
    Li W; Guo Z; Zheng K; Ma K; Cui C; Wang L; Yuan Y; Tang Y
    Int J Pharm; 2017 Dec; 534(1-2):71-80. PubMed ID: 28958879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.